Researchers report sustained suppression of HIV with nevirapine--didanosine--zidovudine.
出版信息
Am J Health Syst Pharm. 1998 Jun 1;55(11):1106, 1108. doi: 10.1093/ajhp/55.11.1106.
PMID:9626369
Abstract
摘要
相似文献
1
Researchers report sustained suppression of HIV with nevirapine--didanosine--zidovudine.
Am J Health Syst Pharm. 1998 Jun 1;55(11):1106, 1108. doi: 10.1093/ajhp/55.11.1106.
2
Maintaining a low viral load with Nevirapine?
TreatmentUpdate. 1998 Dec;10(10):3-4.
3
Development of drug resistance in patients receiving combinations of zidovudine, didanosine and nevirapine.
AIDS. 2001 Jul 6;15(10):1269-74. doi: 10.1097/00002030-200107060-00008.
4
Viral load--how low is best?
TreatmentUpdate. 1998 Dec;10(10):2-3.
5
Rebound of plasma HIV viral load following prolonged suppression with combination therapy.
AIDS. 1998 Jul 30;12(11):1398-9. doi: 10.1097/00002030-199811000-00028.
6
Nevirapine, didanosine, and zidovudine for patients with HIV: the INCAS trial. Italy, Netherlands, Canada, and Australia.
JAMA. 1999 Jan 13;281(2):130; author reply 131.
7
Leukocytopenia due to zidovudine- and nevirapine-containing regimens in elderly patients with HIV infection.
Jpn J Infect Dis. 2000 Dec;53(6):244-5.
8
Nevirapine, didanosine, and zidovudine for patients with HIV: the INCAS trial. Italy, Netherlands, Canada, and Australia.
JAMA. 1999 Jan 13;281(2):130-1.
9
Viramune triple therapy shows suppression of HIV after 1 year, 7 months.
AIDS Patient Care STDS. 1997 Dec;11(6):456-7.
10
Therapeutic advantage of hydroxyurea and didanosine combination therapy in patients previously treated with zidovudine.
AIDS. 1998 Jun 18;12(9):1113-4.
Zotero 插件